Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases

January 7, 2024

https://www.globenewswire.com/news-release/2024/01/08/2805026/0/en/Annexon-Outlines-2024-Priorities-with-Late-Stage-Clinical-Milestones-Across-Upstream-Complement-Portfolio-for-Autoimmune-Ophthalmic-and-Neurodegenerative-Diseases.html

ANX005 Phase 3 Pivotal Data in Guillain-Barré Syndrome (GBS) On Track for First Half of 2024;
Potential to be First Approved Treatment for GBS Patients in the U.S.

Read more at globenewswire.com

Related news for (ANNX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.